News | August 06, 2024
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
Revolutionary technology will further boost OneSource’s scientific services offerings
Revolutionary technology will further boost OneSource’s scientific services offerings
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
GSK and Flagship to jointly fund up to $150 million upfront
Campaign launched to spread awareness regarding dengue prevention and control
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Subscribe To Our Newsletter & Stay Updated
